NIAID funds Kineta for next generation antiviral program
The funding was supported under the Small Business Innovation Research (SBIR) program to provide on-going support for Kineta’s work on a new class of antiviral drugs. The antiviral
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).